Visit https://www.peervoice.com/CCG860 to view the entire programme with slides. After completing “Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC”, participants will be able to: Identify new targets for antibody-drug conjugates and their prevalence and role in patients with NSCLC; Use recommended strategies for detecting expression of novel antigenic targets by tumour cells in patients with NSCLC; and Determine the potential impact of antibody-drug conjugates with novel antigenic targets on later-line treatment strategies in patients with NSCLC.

Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Visit https://www.peervoice.com/NYE860 to view the entire programme with slides. After completing “Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy”, participants will be able to: Assess current treatment options for first-line management of advanced urothelial carcinoma (aUC), including maintenance therapy; Identify patients with aUC who may benefit from maintenance therapy; Formulate appropriate maintenance therapy plans for patients with aUC; and Identify emerging therapies, including maintenance therapies, for the management of aUC.

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Visit https://www.peervoice.com/UGT860 to view the entire programme with slides. After completing “Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer ”, participants will be able to: Assess the clinical relevance of randomised controlled trial (RCT) data evaluating the safety and efficacy of TROP2-directed therapies in the management of HR+/HER2- advanced breast cancer; and Identify patients with HR+/HER2- advanced breast cancer who may benefit from treatment with a TROP2-directed therapy.

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Visit https://www.peervoice.com/GYE860 to view the entire programme with slides. After completing “Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics”, participants will be able to: Assess available safety and efficacy data from randomised clinical trials evaluating first- and next-generation FLT3 inhibitors in acute myeloid leukaemia (AML); Implement best practice approaches to using FLT3 inhibitors in practice, including selecting between therapeutics and utilising recommended dose schedules; and Formulate adverse event management strategies for patients with newly diagnosed FLT3-mutant AML receiving a FLT3 inhibitor, including monitoring and supportive treatment.

Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics

Visit https://www.peervoice.com/ZHK860 to view the entire programme with slides. After completing “Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria”, participants will be able to: Discuss the benefits and limitations of C5 inhibitors in the treatment of paroxysmal nocturnal haemoglobinuria (PNH); Differentiate between breakthrough haemolysis (BTH) and extravascular haemolysis (EVH) in patients who are receiving a terminal complement inhibitor; Evaluate clinically significant EVH in patients with PNH based on signs and symptoms; and Discuss key data on proximal complement inhibitors for the treatment of PNH and their role in clinical practice.

Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC

Download our free app to listen on your phone